var data={"title":"Quetiapine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Quetiapine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6883?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=quetiapine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Quetiapine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=quetiapine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Quetiapine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629647\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709379\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Quetiapine is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidal thoughts and behavior:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients older than 24 years; there was a reduction in risk with antidepressant use in patients 65 years and older. In patients of all ages who are started on antidepressant therapy, monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Quetiapine is not approved for use in pediatric patients younger than 10 years.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216269\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>SEROquel;</li>\n      <li>SEROquel XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216270\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abbott-Quetiapine;</li>\n      <li>ACT-Quetiapine;</li>\n      <li>Apo-Quetiapine;</li>\n      <li>Auro-Quetiapine;</li>\n      <li>Dom-Quetiapine;</li>\n      <li>JAMP-Quetiapine;</li>\n      <li>Mar-Quetiapine ;</li>\n      <li>Mylan-Quetiapine;</li>\n      <li>PHL-Quetiapine;</li>\n      <li>PMS-Quetiapine;</li>\n      <li>PRO-Quetiapine;</li>\n      <li>Quetiapine XR;</li>\n      <li>RAN-Quetiapine;</li>\n      <li>Riva-Quetiapine;</li>\n      <li>Sandoz-Quetiapine;</li>\n      <li>Sandoz-Quetiapine XRT;</li>\n      <li>Seroquel;</li>\n      <li>Seroquel XR;</li>\n      <li>Teva-Quetiapine;</li>\n      <li>Teva-Quetiapine XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216298\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Second Generation (Atypical) Antipsychotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216274\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar disorder:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depressive episodes: </i> <b>Note:</b> In clinical trials, doses up to 600 mg/day were not associated with any further benefit compared to 300 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 50 mg once daily at bedtime on day 1; increase to 100 mg once daily on day 2, further increase by 100 mg daily each day until 300 mg once daily is reached by day 4. Usual dose: 300 mg once daily; maximum dose: 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 50 mg once daily on day 1; increase to 100 mg once daily on day 2, further increase by 100 mg once daily until 300 mg once daily is reached by day 4. Usual dose: 300 mg once daily; maximum dose: 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mania (monotherapy or as an adjunct to lithium or divalproex):</i> Immediate release: Initial: 50 mg twice daily on day 1, further increase by 100 mg daily (administered twice daily) until 200 mg twice daily is reached by day 4; may further increase to 800 mg daily by day 6 in increments of &le;200 mg daily. Usual dosage range: 400 to 800 mg daily; maximum dose: 800 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manic or mixed (monotherapy or as an adjunct to lithium or divalproex):</i> Extended release: Initial: 300 mg once daily on day 1; increase to 600 mg once daily on day 2 then adjust dose to between 400 to 800 mg once daily on day 3; usual dosage range: 400 to 800 mg once daily; maximum dose: 800 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance therapy (adjunct to lithium or divalproex):</i> Immediate release or extended release: Usual dosage range: 400 to 800 mg daily; maximum dose: 800 mg daily. <b>Note:</b> In the maintenance phase, patients generally continue on the same dose on which they were stabilized. Average time of stabilization was 15 weeks in clinical trials. During maintenance treatment, periodically reassess need for continued therapy and the appropriate dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Major depressive disorder (adjunct to antidepressants):</b> Oral: Extended release: Initial: 50 mg once daily on days 1 and 2; increase to 150 mg once daily on day 3. Usual dosage range: 150 to 300 mg daily; maximum dose: 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 25 mg twice daily; increase in increments of 25 to 50 mg divided 2 to 3 times daily on days 2 and 3 to a range of 300 to 400 mg daily in 2 to 3 divided doses by day 4. Further adjustments as needed at intervals of at least 2 days in increments of 25 to 50 mg twice daily. Usual dosage range: 150 to 750 mg daily; maximum dose: 750 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 300 mg once daily; increase in increments of up to 300 mg once daily (in intervals of &ge;1 day). Usual dosage range: 400 to 800 mg once daily; maximum dose: 800 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance therapy (monotherapy):</i> Extended release: Usual dosage range: 400 to 800 mg once daily; maximum dose: 800 mg once daily. <b>Note:</b> During maintenance treatment, periodically reassess need for continued therapy and the appropriate dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delusional infestation (also called delusional parasitosis) (off-label use):</b> Oral: Initial: Immediate release:12.5 mg at bedtime; increase every 3 to 7 days based on response and tolerability up to 200 to 300 mg at bedtime or in divided doses. Maximum: 800 mg/day (Balsco-Fontecilla 2005; Freudenmann 2008; Heller 2013; Milia 2008). Additional data may be necessary to further define the role of quetiapine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Generalized anxiety disorder, monotherapy (off-label):</b> Oral: Extended release: Initial: 50 mg once daily at bedtime; based on response and tolerability, after 3 days increase dose to 150 mg once daily at bedtime; further dosage adjustments up to 300 mg once daily at bedtime may be considered after at least 2 days of 150 mg daily (Bandelow 2010; Katzman 2011; Merideth 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ICU delirium (off-label use):</b> Oral: Immediate release: Initial: 50 mg twice daily; may increase as necessary on a daily basis in increments of 50 mg twice daily to a maximum dose of 400 mg daily (Devlin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obsessive-compulsive disorder, treatment-resistant (augmentation; off-label use):</b> Oral: Immediate release: Initial: 25 to 50 mg once daily; increased gradually based on response and tolerability up to 400 mg/day (Atmaca 2002; Denys 2004; Fineberg 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-traumatic stress disorder (off-label use):</b> Oral: Immediate release: Initial: 25 mg at bedtime; increase dose at 25 mg increments every 1 to 2 days up to 100 mg at bedtime by the end of week 1; further adjust dose based on response and tolerability at increments of 25 mg/day or up to 100 mg/week, to a maximum dose of 400 mg/day administered in 1 or 2 divided doses. Average dose in clinical trials: 100 to 200 mg/day (range: 25 to 400 mg/day) (Ahearn 2006; Hamner 2003; Kozaric-Kovacic 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Switching from immediate release to extended release:</i></b> May convert patients from immediate release to extended release tablets at the equivalent total daily dose and administer once daily; individual dosage adjustments may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Reinitiation of treatment:</i></b> Patients who have discontinued therapy for &gt;1 week should generally be retitrated following reinitiation of therapy; patients who have discontinued &lt;1 week, can generally be reinitiated on their previous maintenance dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage adjustment for concomitant therapy:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant use with a strong CYP3A4 inhibitor (eg, ketoconazole, itraconazole, indinavir, ritonavir, nefazodone):</i> Immediate release or extended release: Decrease quetiapine to one-sixth of the original dose; when strong CYP3A4 inhibitor is discontinued, increase quetiapine by sixfold.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant use with a strong CYP3A4 inducer (eg, phenytoin, carbamazepine, rifampin, St John&rsquo;s wort):</i> Immediate release or extended release: Increase quetiapine up to fivefold of the original dose when combined with chronic treatment (&gt;7 to 14 days) of a strong CYP3A4 inducer; titrate based on clinical response and tolerance; when the strong CYP3A4 inducer is discontinued, decrease quetiapine to the original dose within 7 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy:</b> The manufacturer and American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (APA [Lehman 2004]; Cerovecki 2013; CPA [Addington 2005]; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months, and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA [Addington 2005]). Continuing anti-parkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, 3 strategies have been suggested: cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited, and results are conflicting (Cerovecki 2013; Remington 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216286\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=quetiapine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Quetiapine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar disorder:</b> Children &ge;10 years and Adolescents &le;17 years: Oral: <i>Mania (monotherapy):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 25 mg twice daily on day 1; increase to 50 mg twice daily on day 2, then increase by 100 mg daily (administered twice daily) each day until 200 mg twice day is reached on day 5. May further increase up to 600 mg daily in increments of &le;100 mg daily. Usual dosage range: 400 to 600 mg daily; maximum: 600 mg daily. <b>Note:</b> Total daily doses may also be divided into 3 doses per day, based on response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 50 mg once daily on day 1; increase to 100 mg once daily on day 2, further increase by 100 mg once daily until 400 mg once daily is reached on day 5. Usual dosage range: 400 to 600 mg once daily; maximum dose: 600 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b> Adolescents 13 to &le;17 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 25 mg twice daily on day 1; increase to 50 mg twice daily on day 2, further increase by 100 mg daily each day (divided twice daily) until 400 mg twice daily is reached on day 5. May further increase up to 800 mg daily in increments of &le;100 mg daily. Usual dosage range: 400 to 800 mg daily; maximum dose: 800 mg daily. <b>Note:</b> Total daily doses may also be divided into 3 doses per day, based on response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 50 mg once daily on day 1; increase to 100 mg once daily on day 2, further increase by 100 mg once daily until 400 mg once daily is reached on day 5. Usual dosage range: 400 to 800 mg once daily; maximum dose: 800 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Switching from immediate release to extended release:</i></b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Reinitiation of treatment: </i></b>Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant therapy:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216275\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar disorder or schizophrenia:</b> Oral: Immediate release and extended release: Initial: 50 mg daily; may increase in increments of 50 mg daily to an effective dose, based on individual clinical response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Major depressive disorder (adjunct to antidepressants):</b> Oral: Extended release: 50 mg once daily; may increase by 50 mg once daily to an effective dose, based on individual clinical response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis/agitation associated with dementia (off-label use):</b> Oral: Immediate release: Initial: 25 to 75 mg daily in 1 to 2 divided doses; if necessary, gradually increase based on response and tolerability. Doses as high as 400 to 800 mg/day have been studied. In patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (APA [Reus 2016]; Fujikawa 2004; McManus 1999; Scharre 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis in Parkinson disease (off-label use):</b> Oral: Immediate release: Initial: 25 mg daily in 1 to 2 divided doses; adjust dose gradually based on response and tolerability up to 200 mg daily; mean dose in clinical trials was ~91 mg daily (Merims 2006; Morgante 2004). Additional data may be necessary to further define the role of quetiapine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Switching from immediate release to extended release:</i></b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Reinitiation of treatment:</i></b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage adjustment for concomitant therapy:</i></b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216276\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216277\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immediate release tablet: Initial: 25 mg daily, increase dose by 25 to 50 mg daily to effective dose, based on individual clinical response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extended release tablet: Initial: 50 mg once daily; increase dose by 50 mg once daily to effective dose, based on individual clinical response and tolerability</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216247\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SEROquel: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SEROquel XR: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216234\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874967\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Seroquel: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089126.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlb2Z7OW9begTJQqKmusoacw==&amp;TOPIC_ID=9570\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089126.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Seroquel XR: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM194582.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQcLxxUbgH1HQsIPVkIGGaAA==&amp;TOPIC_ID=9570\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM194582.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5094101\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablet: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablet: Administer without food or with a light meal (&le;300 calories), preferably in the evening. Swallow tablet whole; do not break,  crush, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric/enteral tube (off-label route): Hold tube feeds for 30 minutes before administration; flush with 25 mL of sterile water. Crush dose using immediate-release formulation, mix in 10 mL water and administer via NG/enteral tube; follow with a 50 mL flush of sterile water (Devlin 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216250\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bipolar disorder:</b> Acute treatment of manic (both immediate release and extended release [ER]) or mixed (ER only) episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex; acute treatment of depressive episodes associated with bipolar disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Major depressive disorder (ER only):</b> Adjunctive therapy to antidepressants for the treatment of major depressive disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Schizophrenia:</b> Treatment of schizophrenia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471616\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Obsessive compulsive disorder; Delirium in the critically ill patient; Delusional infestation (also called delusional parasitosis); Generalized anxiety disorder; Post-traumatic stress disorder; Psychosis/agitation associated with dementia; Psychosis in Parkinson disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216306\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">QUEtiapine may be confused with OLANZapine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">SEROquel may be confused with Desyrel, SEROquel XR, Serzone, SINEquan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216241\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Actual frequency may be dependent upon dose and/or indication. Unless otherwise noted, frequency of adverse effects is reported for adult patients; spectrum and incidence of adverse effects similar in children (with significant exceptions noted).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased diastolic blood pressure (&ge;10 mm Hg; children and adolescents: 41% to 47%), increased systolic blood pressure (&ge;20 mm Hg; children and adolescents: 7% to 15%), tachycardia (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (16% to 57%), headache (17% to 21%), agitation (6% to 20%), dizziness (7% to 19%), fatigue (3% to 14%), extrapyramidal reaction (1% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (dose related; 3% to 28%), increased serum triglycerides (&ge;200 mg/dL, 14% to 22%), decreased HDL cholesterol (&le;40 mg/dL, 9% to 20%), total cholesterol increased (&ge;240 mg/dL, 7% to 18%), increased LDL cholesterol (&ge;160 mg/dL, 4% to 12%), hyperglycemia (&ge;200 mg/dL post glucose challenge or fasting glucose &ge;126 mg/dL, 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (adults: 9% to 44%; children and adolescents 4% to 10%), increased appetite (2% to 12%), constipation (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Orthostatic hypotension (2% to 7%; children and adolescents &lt;1%), palpitations (4%), peripheral edema (4%), increased heart rate (2% to 4%), hypotension (3%), hypertension (adults 2%), hypertension (1% to 2%), syncope (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (7%), drug-induced Parkinson disease (2% to &le;6%), lethargy (2% to 5%), dysarthria (2% to 5%), irritability (2% to 5%), akathisia (1% to 5%), hypertonia (4%), twitching (4%), anxiety (2% to 4%), abnormal dreams (2% to 3%), hypersomnia (2% to 3%), paresthesia (2% to 3%), aggressive behavior (children and adolescents 1% to 3%), depression (1% to 3%), dystonic reaction (1% to 3%), abnormality in thinking (2%), ataxia (2%), confusion (2%), decreased mental acuity (2%), disorientation (2%), disturbance in attention (2%), falling (2%), hypoesthesia (2%), lack of concentration (2%), migraine (2%), restless leg syndrome (2%), restlessness (2%), vertigo (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%), acne vulgaris (children and adolescents 2% to 3%), diaphoresis (2%), pallor (children and adolescents 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperprolactinemia (4%), increased thirst (children and adolescents 2%), decreased libido (&le;2%), hypothyroidism (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 10%), vomiting (1% to 8%), dyspepsia (dose related; 2% to 7%), abdominal pain (1% to 7%), gastroenteritis (2% to 4%), toothache (2% to 3%), anorexia (1% to 3%), periodontal abscess (adolescents 1% to 3%), decreased appetite (2%), dysphagia (2%), gastroesophageal reflux disease (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pollakiuria (2%), urinary tract infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (&le;2%), leukopenia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Seasonal allergy (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1% to 10%), tremor (2% to 8%), back pain (1% to 5%), dyskinesia (3% to 4%), arthralgia (1% to 4%), muscle rigidity (3%), muscle spasm (1% to 3%), stiffness (children and adolescents 3%), limb pain (2%), myalgia (2%), neck pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (1% to 4%), amblyopia (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (4% to 6%), nasal congestion (3% to 6%), rhinitis (3% to 4%), epistaxis (adolescents 3%), sinus congestion (2% to 3%), upper respiratory tract infection (2% to 3%), cough (&ge;1% to 3%), dyspnea (&ge;1% to 3%), sinus headache (2%), sinusitis (2%), influenza (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormality of accommodation, abnormal T waves on ECG, abnormal vision, acute renal failure, agranulocytosis, alcohol intolerance, amenorrhea, amnesia, anaphylaxis, anemia, angina pectoris, apathy, aphasia, arthritis, asthma, atrial arrhythmia, atrial fibrillation, atrioventricular block, blepharitis, bone pain, bradycardia, bruxism, buccoglossal syndrome, bundle branch block, candidiasis, cardiomyopathy, cataract, catatonic reaction, cerebral ischemia, cerebrovascular accident, chills, choreoathetosis, conjunctivitis, contact dermatitis, cyanosis, cystitis, deafness, deep vein thrombophlebitis, dehydration, delirium, delusions, dental caries, depersonalization, DRESS syndrome, dysmenorrhea, diabetes mellitus, dysuria, ecchymosis, eczema, ejaculatory disorder, emotional lability, enlargement of abdomen, eosinophilia, euphoria, exfoliative dermatitis, eye pain, facial edema, fecal incontinence, first degree atrioventricular block, flattened T wave on ECG, flatulence, flu-like symptoms, galactorrhea, gastritis, gingival hemorrhage, gingivitis, glaucoma, glossitis, glycosuria, gout, gynecomastia, hallucination, hand edema, hematemesis, hemiplegia, hemolysis, hemorrhoids, hiccups, hyperkinesia, hyperlipemia, hypersensitivity reaction, hyperthyroidism, hyperventilation, hypochromic anemia, hypoglycemia, hypokalemia, hyponatremia, hypothermia, impotence, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased libido, increased serum alkaline phosphatase, increased serum creatinine, increased ST segment on ECG, increased salivation, increased ST segment on ECG, insomnia, intestinal obstruction, inversion T wave on ECG, involuntary body movements, irregular pulse, lactation (females), leg cramps, leukocytosis, leukorrhea, lymphadenopathy, maculopapular rash, malaise, manic reaction, melena, mouth ulceration, myasthenia, myocarditis, myoclonus, neuralgia, neuroleptic malignant syndrome, nightmares, nocturia, orchitis, pancreatitis, paranoid reaction, pathological fracture, pelvic pain, pneumonia, polyuria, priapism, prolonged Q-T interval on ECG, pruritus, psoriasis, psychosis, psychosis, rectal hemorrhage, retrograde amnesia, rhabdomyolysis, seborrhea, seizure, skin discoloration, skin photosensitivity, skin ulcer, SIADH, sleep apnea syndrome (obstructive) (Health Canada 2016, Shirani 2011), somnambulism, Stevens-Johnson syndrome, stomatitis, ST segment changes on ECG, stupor, stuttering, subdural hematoma, suicidal ideation, suicidal tendencies, tardive dyskinesia, taste perversion, thrombocytopenia, thrombophlebitis, tinnitus, tongue edema, toxic epidermal necrolysis, urinary frequency, urinary Incontinence, urinary retention, uterine hemorrhage, vaginal hemorrhage, vaginitis, vasodilatation, vulvovaginal moniliasis, vulvovaginitis, water intoxication, weight loss, widened QRS complex on ECG, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216253\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to quetiapine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216238\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;</b> consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor all patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increased or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. <b>Quetiapine is not approved in the US for use in children &lt;10 years of age.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other antipsychotics, quetiapine has a low potency of cholinergic blockade (Richelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cataracts: Use has been noted to cause cataracts in animals; lens changes have been observed in humans during long-term treatment.  Lens examination, such as a slit-lamp exam, on initiation of therapy and every 6 months is recommended by manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia (ie, Alzheimer disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. All patients should be monitored for symptoms of hyperglycemia (eg, polydipsia, polyuria, polyphagia, weakness) and undergo a fasting blood glucose test if symptoms develop during treatment. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Increases in cholesterol and triglycerides have been noted. Use with caution in patients with pre-existing abnormal lipid profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: May increase prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylactic reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: May cause dose-related decreases in thyroid levels, including cases requiring thyroid replacement therapy. Reversal of thyroid effects occurred in almost all cases following discontinuation. Measure both TSH and free T<sub>4</sub>, along with clinical assessment, at baseline and follow-up to determine thyroid status; measurement of TSH alone may not be accurate (exact mechanism of quetiapine&rsquo;s effect on the thyroid axis is unknown).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability. Rare cases have been reported with quetiapine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, dehydration, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Risk may be minimized by using a low initial dose (eg, immediate release 25 mg twice daily); if hypotension occurs during titration to the target dose, a return to the previous dose in the titration schedule is appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Use has been associated with QT prolongation; postmarketing reports have occurred in patients with concomitant illness, quetiapine overdose, or who were receiving concomitant therapy known to increase QT interval or cause electrolyte imbalance. Avoid use in patients at increased risk of torsade de pointes/sudden death (eg, hypokalemia, hypomagnesemia, history of cardiac arrhythmias, congenital prolongation of QT interval, concomitant medications with QTc interval-prolonging properties). Use with caution in patients at increased risk of QT prolongation (eg, cardiovascular disease, heart failure, cardiac hypertrophy, elderly, family history of QT prolongation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death (APA [Reus 2016]). <b>Quetiapine is not approved for the treatment of dementia-related psychosis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; may increase transaminases (primarily ALT; transient, reversible). Dose adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Patients presenting with depressive symptoms should be screened for bipolar disorder; the screening should include a detailed psychiatric history covering a family history of suicide, bipolar disorder, and depression. Quetiapine is approved in the US for the treatment of bipolar depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotics may aggravate the motor disturbances of Parkinson disease (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease; experience is limited.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Dose escalation should be performed with caution in elderly patients; consider slower rates of dose titration and lower target doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Pharmacologic treatment for pediatric bipolar I disorder or schizophrenia should be initiated only after thorough diagnostic evaluation and a careful consideration of potential risks vs benefits. If a pharmacologic agent is initiated, it should be a component of a total treatment program including psychological, educational and social interventions. Increased blood pressure (including hypertensive crisis) has been reported in children and adolescents; monitor blood pressure at baseline and periodically during use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the manufacturer and American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216291\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216242\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9570&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: QUEtiapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine.  Management: Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing carbamazepine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May enhance the QTc-prolonging effect of QUEtiapine. Clarithromycin may increase the serum concentration of QUEtiapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of QUEtiapine. Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7-14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of QUEtiapine. Management: In quetiapine treated patients, reduce the quetiapine dose to one sixth of the regular dose following strong CYP3A4 inhibitor initiation. In patients receiving strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and up-titrate as needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: May enhance the QTc-prolonging effect of QUEtiapine. QUEtiapine may increase the serum concentration of Methadone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of QUEtiapine. Management: The ritonavir Canadian labeling states this combination should not be used. U.S. labeling recommends using an alternative when possible; if the combination must be used, quetiapine dose reductions are needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: QUEtiapine may enhance the serotonergic effect of St John's Wort. This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of QUEtiapine.  Management: Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7-14 days of discontinuing the inducer. Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216266\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">In healthy volunteers, administration of quetiapine (immediate release) with food resulted in an increase in the peak serum concentration and AUC by 25% and 15%, respectively, compared to the fasting state. Administration of the extended release formulation with a high-fat meal (~800-1000 calories) resulted in an increase in peak serum concentration by 44% to 52% and AUC by 20% to 22% for the 50 mg and 300 mg tablets; administration with a light meal (&le;300 calories) had  no significant effect on the C<sub>max</sub> or AUC. Management: Administer without food or with a light meal (&le;300 calories).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216243\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6831003\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Quetiapine crosses the placenta and can be detected in cord blood (Newport 2007). Congenital malformations have not been observed in humans (based on limited data). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009). The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited, as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is needed in a woman planning a pregnancy or if treatment is initiated during pregnancy, use of quetiapine may be considered (Larsen 2015)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Quetiapine may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to quetiapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850204\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Quetiapine is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of quetiapine is 0.43% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 200 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of quetiapine was calculated using a milk concentration of 62 mcg/L, providing an estimated daily infant dose via breast milk of 9.3 mcg/kg/day. This milk concentration was obtained following maternal administration of quetiapine 200 mg daily throughout pregnancy and after delivery; sampling occurred 3 weeks' postpartum. The RID was calculated using the actual maternal weight. The maximum concentration of quetiapine in breast milk occurred 1 hour after the maternal dose (Lee 2004). In one case report, quetiapine was measured in the serum of a breast fed infant, the concentration was 6% of the maternal level obtained at the same time (Rampono 2007). Adverse events have not been reported in breastfeeding infants (Larsen 2015; Pacchiaarotti 2016; Uguz 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. In general, infants exposed to second generation antipsychotics via breast milk should be monitored weekly for the first month of exposure for symptoms such as appetite changes, insomnia, irritability, or lethargy (Uguz 2016). Although breastfeeding is not recommended by the manufacturer, when an antipsychotic medication is needed in a breastfeeding woman, quetiapine may be used (Larsen 2015; Pacchiaarotti 2016; Uguz 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216256\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">Administer extended release tablet without food or with a light meal (&le;300 calories). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216245\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status; vital signs (as clinically indicated); blood pressure (baseline; repeat 3 months after antipsychotic initiation, then yearly, particularly in children and adolescents); weight, height, BMI, waist circumference (baseline; repeat at 4, 8, and 12 weeks after initiating or changing therapy, then quarterly; consider switching to a different antipsychotic for a weight gain &ge;5% of initial weight); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia); electrolytes and liver function (annually and as clinically indicated); TSH, free T<sub>4</sub>, and thyroid clinical assessment (baseline and follow-up); fasting plasma glucose level/HbA<sub>1c</sub> (baseline; repeat 3 months after starting antipsychotic, then yearly); fasting lipid panel (baseline; repeat 3 months after initiation of antipsychotic; if LDL level is normal, repeat at 2-5 year intervals or more frequently if clinically indicated); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 12 months; high-risk patients every 6 months); lens examination, such as a slit-lamp exam, on initiation of therapy and every 6 months is recommended by manufacturer; alternatively, experts suggest it may be reasonable to inquire yearly about visual changes and perform ocular examinations yearly in patients &gt;40 years or every 2 years in younger patients (ADA 2004; Lehman 2004; Marder 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216237\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Quetiapine is a dibenzothiazepine atypical antipsychotic. It has been proposed that this drug's antipsychotic activity is mediated through a combination of dopamine type 2 (D<sub>2</sub>) and serotonin type 2 (5-HT<sub>2</sub>) antagonism. It is an antagonist at multiple neurotransmitter receptors in the brain: Serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub>, dopamine D<sub>1</sub> and D<sub>2</sub>, histamine H<sub>1</sub>, and adrenergic alpha<sub>1</sub>- and alpha<sub>2</sub>-receptors;  but appears to have no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors. Norquetiapine, an active metabolite, differs from its parent molecule by exhibiting high affinity for muscarinic M1 receptors.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Antagonism at receptors other than dopamine and 5-HT<sub>2</sub> with similar receptor affinities may explain some of the other effects of quetiapine. The drug's antagonism of histamine H<sub>1</sub>-receptors may explain the somnolence observed. The drug's antagonism of adrenergic alpha<sub>1</sub>-receptors may explain the orthostatic hypotension observed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216252\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapidly absorbed following oral administration; high-fat meals (800 to 1000 calories) increase C<sub>max</sub> 8% and AUC 2% of quetiapine XR; light meals (300 calories) had no effect; parent compound AUC and C<sub>max</sub> were 41% and 39% lower, respectively, in pediatric patients (10 to 17 years) compared to adults when adjusted for weight, but pharmacokinetics of active metabolite were similar to adult values after adjusting for weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 10 &plusmn; 4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 83%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic; via CYP3A4; forms the metabolite N-desalkyl quetiapine (active) and two inactive metabolites [sulfoxide metabolite (major metabolite) and parent acid metabolite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 100% (relative to oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 12 to 17 years: Quetiapine: 5.3 hours (McConville 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Mean: Terminal: Quetiapine: ~6 hours; Extended release: ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metabolite: N-desalkyl quetiapine: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 12 to 17 years: Immediate release: 0.5 to 3 hours (McConville 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: 1.5 hours; Extended release: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (73% as metabolites, &lt;1% of total dose as unchanged drug); feces (20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216255\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (QUEtiapine Fumarate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $532.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $955.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,051.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $1,378.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (60): $1,620.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (SEROquel XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $591.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,061.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,168.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $1,532.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (60): $1,800.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (QUEtiapine Fumarate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $399.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $656.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $685.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $1,293.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $1,017.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $1,993.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (SEROquel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $466.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $766.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $800.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $1,509.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $1,187.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $2,325.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216257\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aliquen (AU);</li>\n      <li>Alvoquel (SG);</li>\n      <li>Aretaeus (MX);</li>\n      <li>Atapina (QA);</li>\n      <li>Biatrix (AR);</li>\n      <li>Bipresso (JP);</li>\n      <li>Biquelle XL (GB);</li>\n      <li>Cacepin (KR);</li>\n      <li>Calm-EZ (TW);</li>\n      <li>Catepsin (PY);</li>\n      <li>Delucon (AU);</li>\n      <li>Ebesque XL (GB);</li>\n      <li>Edagan (PE, UY);</li>\n      <li>Geroquel (IE);</li>\n      <li>Gofyl (CL);</li>\n      <li>Hedonin (LV);</li>\n      <li>Hiloca (TW);</li>\n      <li>Kesaquil (HK);</li>\n      <li>Ketilept (LV, PH);</li>\n      <li>Ketipinor (MY, SG);</li>\n      <li>Ketylept (UA);</li>\n      <li>Kitapen (BR);</li>\n      <li>Kventiax (LV);</li>\n      <li>Kvetipin (UA);</li>\n      <li>Limus (TW);</li>\n      <li>Mintreleq XL (GB);</li>\n      <li>Neutapin (TH, TW);</li>\n      <li>Ovex (LK);</li>\n      <li>Q-Win (PH);</li>\n      <li>Qmax (BD);</li>\n      <li>Qtipine (PH);</li>\n      <li>Quantia (HK, PH, TW);</li>\n      <li>Quentiax (IE);</li>\n      <li>Querok (BR);</li>\n      <li>Quetapel (NZ);</li>\n      <li>Quetapin (KR);</li>\n      <li>Quetiap RD (PH);</li>\n      <li>Quetiateg (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Quetiazic (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Quetidin (CO, EC, PY);</li>\n      <li>Quetinil (BD);</li>\n      <li>Quetvell (ID);</li>\n      <li>Quety (KR);</li>\n      <li>Quiet (BD);</li>\n      <li>Quipine (AU);</li>\n      <li>Qurax (CL);</li>\n      <li>Qutiapine (KR);</li>\n      <li>Qutipin (KR);</li>\n      <li>Rezal XR (AE, QA);</li>\n      <li>Sequase (CH);</li>\n      <li>Seroquel (AE, AR, AT, BB, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CU, CY, CZ, DE, DK, EC, EE, ES, FI, GB, GR, GY, HK, HR, ID, IE, IL, IS, IT, JM, JO, KR, KW, LB, LK, LT, LU, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SR, TH, TR, TT, TW, UY, VE, VN);</li>\n      <li>Seroquel IR (HK);</li>\n      <li>Seroquel Prolong (IS);</li>\n      <li>Seroquel SR (SI);</li>\n      <li>Seroquel XR (AU, BB, CH, CN, CU, CY, GB, HK, HR, ID, IL, KW, LB, LK, LT, LU, LV, MT, MY, PH, QA, RO, SG, SK, TH, UA, VN);</li>\n      <li>Seroquet (BD);</li>\n      <li>Serotia (PH);</li>\n      <li>Serroquel XR (AE);</li>\n      <li>Setinin (HK, MT);</li>\n      <li>Smoodipin (KR);</li>\n      <li>Socalm (IN);</li>\n      <li>Sondate XL (GB);</li>\n      <li>Squro (TH);</li>\n      <li>Tevaquel (IE);</li>\n      <li>Tiamax (CO);</li>\n      <li>Toliken (BD);</li>\n      <li>Torquite SR (TZ, ZW);</li>\n      <li>Utapine (TW);</li>\n      <li>Vesparax (AR);</li>\n      <li>Victus (PH);</li>\n      <li>Zaluron XL (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16317314\"></a>Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. <i>Int Clin Psychopharmacol</i>. 2006;21(1):29-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16317314/pubmed\" target=\"_blank\" id=\"16317314\">16317314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15003083/pubmed\" target=\"_blank\" id=\"15003083\">15003083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi: 10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo; <i>Breastfeed Med</i>, 2007, 2(1):10-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17661614/pubmed\" target=\"_blank\" id=\"17661614\">17661614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment-resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. <i>Int Clin Psychopharmacol</i>. 2002;17(3):115-119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11981352/pubmed\" target=\"_blank\" id=\"11981352\">11981352</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19691907\"></a>Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. <i>Int J Neuropsychopharmacol</i>. 2010;13(3):305-320.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19691907/pubmed\" target=\"_blank\" id=\"19691907\">19691907</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bandelow B, Zohar J, Hollander E, Kasper S, M&ouml;ller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World J Biol Psychiatry</i>. 2008;9(4):248-312. doi: 10.1080/15622970802465807.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18949648/pubmed\" target=\"_blank\" id=\"18949648\">18949648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: American Psychiatric Association, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blasco-Fontecilla H, Bragado Jim&eacute;nez MD, Garc&iacute;a Santos LM, Barjau Romero JM. Delusional disorder with delusions of parasitosis and jealousy after stroke: treatment with quetiapine and sertraline. <i>J Clin Psychopharmacol</i>. 2005;25(6):615-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16282853/pubmed\" target=\"_blank\" id=\"16282853\">16282853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denys D, de Geus F, van Megen HG, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. <i>J of Clin Psychiatry</i>. 2004;65(8):1040-1048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15323587/pubmed\" target=\"_blank\" id=\"15323587\">15323587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19915454\"></a>Devlin JW, Roberts RJ, Fong JJ, et al, &ldquo;Efficacy and Safety of Quetiapine in Critically Ill Patients With Delirium: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study,&rdquo; <i>Crit Care Med</i>, 2010, 38(2):419-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19915454/pubmed\" target=\"_blank\" id=\"19915454\">19915454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dixon L, Perkins D, and Calmes C, <i>Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia</i>, Arlington, Va: American Psychiatric Association, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22932229\"></a>Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. <i>Int J Neuropsychopharmacol</i>. 2013;16(3):557-574. doi: 10.1017/S1461145712000740.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22932229/pubmed\" target=\"_blank\" id=\"22932229\">22932229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. <i>Int Clin Psychopharmacol</i>. 2005;20(4):223-226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15933483/pubmed\" target=\"_blank\" id=\"15933483\">15933483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18794644\"></a>Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol</i>. 2008;28(5):500-508<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18794644/pubmed\" target=\"_blank\" id=\"18794644\">18794644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15118358\"></a>Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. <i>Neuropsychobiology</i>. 2004;49(4):201-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15118358/pubmed\" target=\"_blank\" id=\"15118358\">15118358</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12544370\"></a>Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. <i>J Clin Psychopharmacol</i>. 2003;23(1):15-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12544370/pubmed\" target=\"_blank\" id=\"12544370\">12544370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/antipsycho2-eng.php. Published August 16, 2016. Accessed August 23, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heller MM, Wong JW, Lee ES, et al. Delusional infestations: clinical presentation, diagnosis and treatment. <i>Int J Dermatol</i>. 2013;52(7):775-783.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23789596/pubmed\" target=\"_blank\" id=\"23789596\">23789596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendrickson RG and Morocco AP, &ldquo;Quetiapine Cross-Reactivity Among Three Tricyclic Antidepressant Immunoassays,&rdquo; <i>Clin Toxicol</i>, 2003, 41(2):105-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12733845/pubmed\" target=\"_blank\" id=\"12733845\">12733845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20881846\"></a>Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.<i> Int Clin Psychopharmacol</i>. 2011;26(1):11-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20881846/pubmed\" target=\"_blank\" id=\"20881846\">20881846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21694613\"></a>Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. <i>J Clin Psychopharmacol</i>. 2011;31(4):418-428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21694613/pubmed\" target=\"_blank\" id=\"21694613\">21694613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association, 2007. Available online at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16945162\"></a>Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. <i>Int J Neuropsychopharmacol</i>. 2007;10(2):253-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16945162/pubmed\" target=\"_blank\" id=\"16945162\">16945162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17650054/pubmed\" target=\"_blank\" id=\"17650054\">17650054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. <i>Am J Psychiatry</i>. 2004;161(9):1715-1716.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15337669/pubmed\" target=\"_blank\" id=\"15337669\">15337669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15285957/pubmed\" target=\"_blank\" id=\"15285957\">15285957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McConville BJ, Arvanitis LA, Thyrum PT, et al, &ldquo;Pharmacokinetics, Tolerability, and Clinical Effectiveness of Quetiapine Fumarate: An Open-Label Trial in Adolescents With Psychotic Disorders,&rdquo; <i>J Clin Psychiatry</i>, 2000, 61(4):252-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10830145/pubmed\" target=\"_blank\" id=\"10830145\">10830145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10362435\"></a>McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. <i>J Clin Psychiatry</i>. 1999;60(5):292-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10362435/pubmed\" target=\"_blank\" id=\"10362435\">10362435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22045039\"></a>Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.<i> Int Clin Psychopharmacol</i>. 2012;27(1):40-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22045039/pubmed\" target=\"_blank\" id=\"22045039\">22045039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17095896\"></a>Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. <i>Clin Neuropharmacol</i>. 2006;29(6):331-337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17095896/pubmed\" target=\"_blank\" id=\"17095896\">17095896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23070803\"></a>Mezhebovsky I, M&auml;gi K, She F, Datto C, Eriksson H. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. <i>Int J Geriatr Psychiatry</i>. 2013;28(6):615-625.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23070803/pubmed\" target=\"_blank\" id=\"23070803\">23070803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18836354\"></a>Milia A, Mascia MG, Pilia G, et al. Efficacy and safety of quetiapine treatment for delusional parasitosis: experience in an elderly patient. <i>Clin Neuropharmacol</i>. 2008;31(5):310-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18836354/pubmed\" target=\"_blank\" id=\"18836354\">18836354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miyasaki JM, Shannon K, Voon V, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.<i> Neurology</i>. 2006;66(7):996-1002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16606910/pubmed\" target=\"_blank\" id=\"16606910\">16606910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15319699\"></a>Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. <i>Clin Neuropharmacol</i>. 2004;27(4):153-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15319699/pubmed\" target=\"_blank\" id=\"15319699\">15319699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Calamaras MR, DeVane CL, et al, &quot;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&quot; <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17671284/pubmed\" target=\"_blank\" id=\"17671284\">17671284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacchiarotti I, Le&oacute;n-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27568278/pubmed\" target=\"_blank\" id=\"27568278\">27568278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rampono J, Kristensen JH, Ilett KF, Hackett LP, Kohan R. Quetiapine and breast feeding. <i>Ann Pharmacother</i>. 2007;41(4):711-714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17374621/pubmed\" target=\"_blank\" id=\"17374621\">17374621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.27133416</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60 suppl 10:5-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10340682/pubmed\" target=\"_blank\" id=\"10340682\">10340682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12040309\"></a>Scharre DW, Chang SI. cognitive and behavioral effects of quetiapine in Alzheimer disease patients. <i>Alzheimer Dis Assoc Disord</i>. 2002;16(2):128-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12040309/pubmed\" target=\"_blank\" id=\"12040309\">12040309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seroquel XR (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21645873/pubmed\" target=\"_blank\" id=\"21645873\">21645873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16904298\"></a>Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. <i>Eur Neuropsychopharmacol</i>. 2007;17(2):79-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16904298/pubmed\" target=\"_blank\" id=\"16904298\">16904298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17390261/pubmed\" target=\"_blank\" id=\"17390261\">17390261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22143997\"></a>Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. <i>Hum Psychopharmacol</i>. 2011;26(8):614-628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22143997/pubmed\" target=\"_blank\" id=\"22143997\">22143997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27028982/pubmed\" target=\"_blank\" id=\"27028982\">27028982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ursano RJ, Bell CB, Eth S, Friedman M, Norwood A, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: American Psychiatric Association, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo; <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17316169\"></a>Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia; a randomized, double-blind, placebo-controlled study. <i>Curr Alzheimer Res</i>. 2007;4(1)81-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17316169/pubmed\" target=\"_blank\" id=\"17316169\">17316169</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9570 Version 268.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629647\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709379\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216269\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216270\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F216298\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F216274\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F216286\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F216275\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F216276\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F216277\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216247\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F216234\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874967\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5094101\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F216250\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471616\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216306\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216241\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216253\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216238\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F216291\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216242\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F216266\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F216243\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6831003\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9850204\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F216256\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F216245\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216237\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F216252\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F216255\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F216257\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9570|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=quetiapine-patient-drug-information\" class=\"drug drug_patient\">Quetiapine: Patient drug information</a></li><li><a href=\"topic.htm?path=quetiapine-pediatric-drug-information\" class=\"drug drug_pediatric\">Quetiapine: Pediatric drug information</a></li></ul></div></div>","javascript":null}